Please login to the form below

Not currently logged in
Email:
Password:

Eisai launches online obesity awareness drive

Wants US employers to realise the cost of obesity

Eisai obesity websiteEisai has launched a new online campaign to highlight the cost of obesity to US employers.

Its Closing the Gap: Obesity Management for Employers site will feature articles, case studies, presentations, and has been designed to complement an existing newsletter.

Dave Martin, vice president of managed markets, value and access for Eisai, said: "We know from our research that most employers consider obesity to be a top employee health challenge. While there are some helpful resources available for employers, we also noted significant gaps; therefore, we decided to build this all-inclusive website."

The website, sponsored by Eisai and maintained by The Benfield Group, aims to provide employers with a “dedicated source for actionable information on obesity management”.

The pharma company's key therapy in the area is Belviq (lorcaserin HCl). The drug is being co-marketed with Arena Pharmaceuticals and in June it became the first new obesity treatment drug to be approved in the US in 15 years. 

The FDA gave it the green light for use as an add-on to a reduced calorie diet and increased exercise for weight management. 

28th August 2013

From: Marketing

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics